COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN MEXICO

被引：0
|
作者：
Vargas-Valencia, J. [1 ]
Sotelo-Guzman, M. [1 ]
Mould-Quevedo, J. F. [2 ]
Mucino-Ortega, E. [3 ]
Galindo-Suarez, R. M. [3 ]
机构：
[1] Econopharma Consulting SA CV, Mexico City, DF, Mexico
[2] Pfizer, New York, NY USA
[3] Pfizer, Mexico City, DF, Mexico
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 03期
关键词：
D O I：
10.1016/j.jval.2011.02.707
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A127 / A127
页数：1
相关论文
共 50 条
  • [21] Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
    Diamantopoulos, Alex
    Finckh, A.
    Huizinga, T.
    Sungher, D. K.
    Sawyer, L.
    Neto, D.
    Dejonckheere, F.
    [J]. PHARMACOECONOMICS, 2014, 32 (08) : 775 - 787
  • [22] Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
    Alex Diamantopoulos
    A. Finckh
    T. Huizinga
    D. K. Sungher
    L. Sawyer
    D. Neto
    F. Dejonckheere
    [J]. PharmacoEconomics, 2014, 32 : 775 - 787
  • [23] Cost-effectiveness analysis of tofacitinib compared with adalimumab and etanercept in the treatment of severe active rheumatoid arthritis; Iranian experience
    Fatemi, Behzad
    Rezaei, Soheila
    Taheri, Saeed
    Peiravian, Farzad
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (04) : 775 - 784
  • [24] Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea
    Park, Sun-Kyeong
    Park, Seung-Hoo
    Lee, Min-Young
    Park, Ji-Hyun
    Jeong, Jae-Hong
    Lee, Eui-Kyung
    [J]. CLINICAL THERAPEUTICS, 2016, 37 (11) : 2430 - 2446
  • [25] The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis
    Vergel, Y. Bravo
    Hawkins, N. S.
    Claxton, K.
    Asseburg, C.
    Palmer, S.
    Woolacott, N.
    Bruce, I. N.
    Sculpher, M. J.
    [J]. RHEUMATOLOGY, 2007, 46 (11) : 1729 - 1735
  • [26] A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness
    Chen, Y-F
    Jobanputra, P.
    Barton, P.
    Jowett, S.
    Bryan, S.
    Clark, W.
    Fry-Smith, A.
    Burls, A.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2006, 10 (42) : 1 - +
  • [27] COST-EFFECTIVENESS OF THE USE OF ETANERCEPT VS ANTI-TNF MONOCLONAL ANTIBODIES IN PATIENTS WITH RHEUMATOID ARTHRITIS IN MEXICO
    Aguirre, A.
    Garcia, E.
    Bierschwale, H.
    Arce, C. A.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A522 - A523
  • [28] Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis (RA) in the UK.
    Brennan, A
    Bansback, N
    Conway, P
    Reynolds, AV
    [J]. ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S157 - S157
  • [29] Cost-effectiveness of the treatment for early rheumatoid arthritis in Mexico:: Infliximab vs. adalimumab
    Mucino, E.
    Rivas, R.
    Zapata, L.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A259 - A259
  • [30] ABATACEPT FOR THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS IN ARGENTINA: A COST-EFFECTIVENESS ANALYSIS
    Elgart, J. F.
    Gonzalez, L.
    Aiello, E. C.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A223 - A224
12345